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The diagnosis of autoimmune blistering skin disease is in-
creasingly based on the skin antigen(s) that is the target of the 
autoimmune process. Some patients with bullous diseases 
have unusual basement membrane autoantibodies that react 
to antigens present in both the epidermal and dermal sides of 
skin split with 1 M NaCI. This combined staining pattern is 
due to antibodies directed in part to a 160-kilodalton (kD) 
basement membrane antigen present on the epidermal side of 
the split skin and to different antigen(s) present on the dermal 
side. The identity of the current antigen(s), and the signifi-
cance of this unusual type of combined staining antibody 
response is not known. 
Sera of five patients with combined staining antibodies, 19 
~atients with other types of basement membrane antibodies 
(15 directed only to the epidermal and four only to the der-
mal side of split skin), and 23 patients without basement 
membrane antibodies were tested by Western immunoblot 
for reactivity to 4% sodium dodecyl sulfate + 2 M urea ex-
tracts of dermal and epidermal side of salt-split skin. Three 
(60%) of the combined staining sera had antibodies to an 
Autoimmune subepidermal bullous skin diseases are classically distinguished by clinical and histologic findings, and by the presence of circulating and tissue-fixed basement membrane antibodies detected by im-munofluorescence techniques. More recently, how-
ever, these diseases are differentiated based on the skin antigen(s) 
that is the target of the autoimmune process [1- 3]' Two recent 
advances improve the ability to differentiate among the diseases. 
One is to test the reactivity of the antibodies against skin split with 
1 M sodium chloride, a procedure that separates skin in the middle 
of the lamina lucida zone of the basement membrane. This permits 
localization of basement membrane antigens that are the target of 
the autoantibodies at the ultrastructural level as being either on the 
epidermal or dermal side of the mid-lamina lucida [4] . The other is 
to use Western blotting or immunoprecipitation techniques to 
identify these antigens at the molecular level. Using these proce-
dures, it is possible to distinguish bullous pemphigoid (BP) from 
epidermolysis bullosa acquisita (EBA), two diseases that are other-
wise similar clinically, histologically, and by conventional immu-
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82- 84-kD antigen (p84) reproducibly present in dermal, but 
not epidermal, extracts of normal human skin. Antibodies to 
this antigen were absent in the 42 control sera. Western blot 
affinity-purified antibody to p84 bound only to the basement 
membrane, on the dermal side of 1 molar salt-split skin. By 
co-migration experiments, p84 differed from other basement 
membrane antigens including the major and minor bullous 
pemphigoid, cicatrizing pemphigoid, and epidermolysis bul-
losa acquisita antigens, types III and IV collagen, laminin, 
and epiligrin. 
Thus, combined staining antibodies are directed in part to 
an 82- 84-kD antigen (p84), a normal but previously unde-
scribed component of the basement membrane of human 
skin. This antigen differs from the basement membrane anti-
gens recognized by autoantibodies in other subepidermal 
bullous diseases. The antibody response to p84 provides a 
specific marker for a novel autoimmune subepidermal blis-
tering skin disease. Key words: combined staining sera/bul_ 
lous pemphigoid/bullous diseases/epidermolysis bullosa acquisita. 
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nofluorescence tests [5] . The circulating basement membrane anti-
bodies in BP are directed to antigens of 230 and 160 - 180 kDs [6] 
present on the epidermal side of skin split with 1 M NaCI, whereas 
in EBA they are directed to 145- and 290-kD antigens [7] present on 
the dermal side [4] . The same procedures have been used to establish 
the presence of antibodies to epiligrin, a component of the basement 
membrane, which is the major keratinocyte integrin ligand, as a 
specific marker for a novel autoimmune subepidermal blistering 
disease [8] . 
However, some patients with subepidermal bullous diseases have 
unusual basement membrane antibodies that react to both the epi-
dermal and the dermal side of skin split with 1 M NaCI [7 - 9]. This 
combined staining (CS) pattern is reproducible, and is not due to a 
technical artifact of splitting skin with salt [10] . Prior work fro In 
our laboratory indicates that it results from a unique and complex 
antibody response directed in part to antigens present on the epider-
mal side and in part to antigens present on the dermal side of the split 
[10]. The epidermal antigens defined by CS se'ra have been identi-
fied as proteins of 160-180 kD and 230 kD, which co-migrate 
with, and thus may be similar to, the minor and major BP antigens 
[10]. The antigen(s) defined by the antibodies directed to the dermal 
side of the split skin are unknown. 
The clinical relevance of this unusual type of combined antibody 
response is not known. We have suggested it may represent the 
manifestation of a novel bullous disease [10] , but this has been diffi-
cult to confirm absent firm evidence that such patients develop 
0022-202X/94/S07.00 Copyright © 1994 by The Society for Investigative Dermatology, Inc. 
236 
VOL. 102, NO.2 FEBRUARY 1994 p84, A NOVEL BASEMENT MEMBRANE ANTIGEN 237 
Table I. Characteristics of Study Population 
Sera 
Positive 
Negative 
Total 
Staining Pattern 
on Salt-Split Skin 
Combined 
Epidermal 
Dermal 
• Both patients had bullous LE. 
Number 
of Patients 
5 
15 
4 
23 
47 
antibody responses to antigens that differ from those seen by pa-
tients with classical BP or EBA. 
The following study, conducted to identify dermal antigens re-
active with CS sera, has led to the identification of a novel compo-
nent of the basement membrane, denominated p84, which has a 
molecular weight (MW) of approximately 82,000-84,000. Anti-
body responses to this antigen appe:u- restricted to pat.ie~ts with C.S 
antibodies, suggestmg that such patients may have a dlstmct subepi-
dermal bullous disease. 
MATERIALS AND METHODS 
Sera Studies were conducted with sera of five patients with CS antibodies 
(titer 80 - 320 against intact tissue) that reacted with both the epidermal and 
dermal side of Usa It-split" human skin (see below) of23 patients with bullous 
diseases and no detectable basement membrane antibodies by indirect immu-
nofluorescence against monkey and guinea pig esophagus, and of 19 patients 
with basement membrane antibodies (titer 40 -1280) that reacted only to the 
epidermal side (15 sera) or to the dermal side (four sera) of salt-split human 
skin. The clinical diagnoses of these patients are summarized in Table 1. 
Monoclonal antibodies used included PHM12 to human collagen Type 
IV (ICN Biomedicals, Inc., Costa Mesa, CA), J3 ascites HIGS to human 
collagen III, AEt lAE) MIX to epithelial keratin (ICN) and to laminin 
(ICN), PIEI to epiligrin (Or. William G. Carter, Fred Hutchinson Cancer 
Center, Seattle, WA). 
Indirect Immunofluorescence This was performed by a standard tech-
nique as previously described [10). Substrates included monkey and guinea 
pig esophagus and normal human skIn. 
1 M NaCl-Split Skin This was performed as described by Gammon et 
al [4). Our method has been published [10). 
Tissue Extracts Extracts of normal human epidermis and dermis were 
prepared from surgical ~pecimens ?f mastecto~y obtained fro~ four differ-
ent individuals. The skIn was cut Into small pieces, Incubated In 1 M NaCI 
containing 2 mM ethylenediaminetetraacetate (EDT A) and 1 mM phenyl-
methylsulphonyl fluoride (PMSF) at 4°C for 48-72 h, and the epidermis 
separated from the dermis with forceps. The dermis and epidermis were 
washed with phosphate-buffered saline (PBS) X 3, and 1-cm pieces of tissue 
were then separately incubated in 1 ml extraction buffer (4% sodium dode-
cylsulfate [SDS), 2 M urea, 1 mM PMSF, 2 mM EDTA in Tris buffer) for 
48 h at 4 ° C in a shaker. The tissues were then removed by centrifugation at 
500 X g, the supernatants centrifuged at 8800 X g for 30 min, concentrated, 
and stored at -70°C until used. Protein concentration was adjusted to 1.19 
mg/ml for dermal and 1.56 mg/ml for epidermal extracts. 
Some extracts were also prepared by homogenizing skin in 2% SDS, 
1 mM PMSF, 2 mM EOTA, and 0.1 M dithiothreitol (OTT) as described by 
Stanley [11) and by vortexing dermis in 12.5 mM Tris-HCI buffer contain-
ing 8 M urea, 2% SDS, 1 mM PMSF, 2 mM EOTA, and 0.1 M OTT as 
described by Woodley [7). These procedures solubil;ze BP and EBA anti-
gens, respectively. 
SDS-PAGE and Western Immunoblot Tissue extracts were boiled for 
5 min in sample buffer (10% glycine, 20 mM EOTA, 6% SOS, 0.008% 
bromphenol blue, and 5% mercaptoethanol in 62.4 mM Tris -HCI [pH 
6.8)) and 400-lambda aliquots electrophoresed on 8% or 5% polyacrylamide 
slab gels in the presence of 0.1 % SDS as described by Laemmli [12) and 
transferred to nitrocellulose sheets according to Towbin [13). Specific anti-
gens were visualized by incubating individual lanes sequentially with 3% 
non-fat milk in PBS pH 7.4 for 2 h to block non-specific binding, patient's 
serum diluted 1: 50 in PBS with 3% non-fat milk pH 7.4 at room tempera-
ture for 4 h, and with biotin-conjugated goat affinity-purified antibody to 
human IgG (Organon Teknika Corporation; Cappel Research Products, 
Clinical Diagnosis 
BP CP EBA PV Others 
5 0 0 0 0 
9 6 0 0 0 
0 0 2 0 2' 
0 0 0 8 15 
14 6 2 8 15 
Durham, NC) for 2 h, and with peroxidase-conjugated avidin (Organon) 
for another 1 h at room temperature. Reaction products were developed 
with 0.3% 4 chloro-naphthol and 0.03% H20 2. 
Affinity Purification of Antibody Antibodies to dermal antigens in a 
combined staining serum (no. 10504) were affinity purified by incubating 
1 ml of a 1 : 5 dilution of the serum with a 2-X-3-cm piece of the dermal side 
of salt-split human skin for 90 min at 27°C. The specimen was then washed 
thoroughly with PBS for 30 min. Bound antibody was eluted with 5 ml of 
0.02 M sodium citrate, pH 2.3, for 20 min, neutralized with 2 M tris base pH 
9.0, dialyzed against tris-buffered saline, and concentrated tenfold by ultra-
filtration using a Centricon 10 microconcentrator (Amicon; W .R. Grace & 
Co., Danvers, MA). 
Specific antibody to p84 was affinity purified by a modification of the 
method described by Mueller [14). Extracts of normal human dermis were 
separated by SOS-polyacrylamide gel electrophoresis (PAGE), as described 
above, and electrophoretically transferred to nitrocellulose sheet. One verti-
cal strip on each side of the sheet was cut out, incubated with CS serum 
10504 containing antibody to p84, and stained with peroxidase. These strips 
were used to locate the unstained p84 antigen in the remaining lanes on the 
nitrocellulose sheet and a 0.5 -1.0-cm wide horizontal strip containing this 
antigen was cut. A strip of equal width containing a 200-kD antigen was also 
cut as a control. Each strip was incubated with 1 ml of a 1 : 5 dilution of serum 
10504 for 16 h at 4°C, washed with 0.5% Tween 20 in TBS buffer X 3; and 
bound antibody eluted with 2 ml of 0.5 M glycine in 0.5 M NaCI, pH 2.3, 
at 27°C for 20 min. The eluate was collected, neutralized immediately with 
0.5 M Na2HPO., pH 6.5, dialyzed, and concentrated tenfold by ultrafiltra-
tion as described above. 
RESULTS 
Anatomical Location of Dermal Antigen(s) Defined by 
Combined Staining Antibodies The initial experiments were 
conducted to examine whether the dermal antigen(s) defined by CS 
sera are present only in the dermal side of salt-split skin or whether 
they straddle the lamina lucida region split by 1 M NaCI. To inves-
tigate this possibility, the antibodies in a CS serum that reacted with 
dermal antigens were affinity purified against the dermal side of 
salt-split skin as described in Materials and Methods, and tested for 
reactivity against 1 M NaCI-split skin by indirect immunofluores-
cence. The non - affinity-purified serum reacted against both the 
dermal and the epidermal side of the split skin (see Fig 1A). By 
contrast, affinity-purified antibodies reacted only against the dermal 
side of the split skin. (Fig 1B). These results indicate that some of the 
antibodies in CS sera are directed to antigens present solely on the 
dermal side of the split skin. 
Dermal Antigen(s) Defined by Antibodies in Combined 
Staining Sera The profile of dermal antigens defined by CS anti-
bodies in five patients was examined by Western blot analysis, using 
as an antigen source 4% SDS + 2 M urea extracts of dermis. Anti-
bodies in three of the patients reacted to an antigen of approximately 
82-84 kDs denominated p84 (Fig 2, lanes 1-3). Identical results 
were obtained in additional experiments using extracts prepared 
similarly from three different specimens of skin. No antibodies to 
this antigen were detected in sera of23 individuals without detecta-
ble circulating basement membrane antibodies, or in 19 individuals 
with circulating basement membrane antibodies that reacted only to 
the epidermal or to the dermal side of split skin (see Table II). 
In experiments conducted to examine its solubility properties, 
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Figure 1. Anatomical location of dermal antigen(s) defined by combined 
staining sera. Immunofluorescence photomicrograph of 1 M NaCI-split 
normal human skin reacted with A) combined staining serum (10504). B) 
the dermal reacting antibodies in this serum that were affinity purified. as 
described in Materials and Met!'ods, and C) normal human serum control. (.). 
reaction to epidermal; (.). reaction to dermal side of split skin. Scale bar, 
50 tJ.. 
p84 was not detected in dermis extracted with 0.5% NP-40, 2% 
SDS with 2 M or 8 M urea, 2% SDS with 0 .1 M DTT, or by 
mechanical scraping of the upper side of split dermis in tris buffer 
with 0.1 M DTT. 
Combined staining sera also had antibodies to one or more anti-
gens of approximately 180-200 kD in the 4% SDS + 2 M urea 
1234567 
Figure 2. Dermal antigens defined by combined staining sera. Western 
immunoblots of combined staining (lan es 1-5) and normal human sera (lane 
6) reacted with 4% SDS + 2 M urea dermal extract of normal human skin. 
Arrow, reaction to 84-kD antigen. Lane 7, PBS control; lane 1, serum 10504 
used in subsequent affinity-purification experiments. 
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Table II. Incidence of Antibodies to p84 
Staining Pattern 
versus Salt-Split Skin 
Combined 
Epidermal 
Dermal 
Noneb 
• By Western immunoblot. 
Number 
of Sera 
5 
15 
4 
23 
Antibodies· 
to p84 (%) 
3 (60) 
0(0) 
0(0) 
0(0) 
! Control sera with no detectable circulating anti-basement membrane antibodies. 
dermal extracts (see Fig 2). Similar antibodies were also observed in 
some BP, cicatrizing pemphigoid (CP), and normal sera. The sig_ 
nificance of these antibodies has not been further investigated at this 
time. 
Relation of p84 to Other Epidermal and Dermal Anti_ 
gens p84 appears to differ from the antigens defined by autoanti_ 
bodies in patients with classic types of autoimmune blistering dis-
eases. No antibodies to p84 were detected in sera of19 patients (nine 
BP, six CP, two EBA, and two bullous lupus erythematosus) with 
basement membrane antibodies (titer 40 - 1280) that reacted only to 
the epidermal or to the dermal side of salt-split skin when tested 
concurrently against a 4% SDS + 2 M urea dermal extract that 
strongly expressed p84 (see Fig 3 for representative results) . Nor 
were antibodies to p84 present in eight intercellular antibody-posi_ 
tive sera (titer 40-1280) from pemphigus vulgaris patients (see 
Table I). ' 
It is of note that the method we used to extract p84 did not 
solubilize the 145- or 290-kD antigens defined by EBA sera. Con-
versely, the method did solubilize a 125-kD dermal antigen (see 
Fig 3, lanes 5,6), which w as reactive with three of nine BP patients 
but not with CS sera or with sera of 12 other patients with bullous 
diseases unrelated to BP. In concurrent experiments, antibody to 
p84 and to the 125-kD antigen reacted independently to their re -
spective target antigens, indicating these two antigens differ physi-
cally in size and are not the result of experimental variations in the 
migration of one or the other in SDS-PAGE. 
p84 did not co-migrate with types III or IV collagen, and the 
conditions used to solubilize p84 did not solubilize laminin, a mix-
ture of keratins, or epiligrin (see Fig 4). Co-migration experiments 
were subsequently repeated with affinity-purified antibody to p84 
prepared by elution from Western blots as described in Materials arId 
12S ..... 
84-
1 
11 
() t'!I ~ to III lI>' 
Figure 3. Relation of p84 to antigens defined by autoantibodies in patients 
with autoimmune blistering diseases. Western immunoblots of dermal ex-
tracts of normal human skin reacted with combined staining sera (lan es 
1- 3), or with scra of patients with BP (lan es 4-8), cicatrizing pemphigoid 
(lan es 9-13), EBA (lan es 14,15), or pemphigus vulgaris (lanes 16- 18) . All 
sera had high titers of basement membrane or intercellular antibodies by 
indirect immunofluorescence. Lanes 19 and 20 arc normal human serum and 
PBS controls, respectively. 
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Figure 4. Relation of p84 to other epidermal and dermal antigens. Western 
immunoblots of dermal extracts of normal human skin reacted with com-
bined staining serum with antibodies to p84 (lalle 1), or with monoclonal 
antibody to type III collagen (lalle 2), to type IV collagen (folie 3), to laminin 
(lane 4), to keratin mix (lane 5), to epiligrin (laue 6), and normal human 
serum (lane 7) or PBS (lalle 8) . 
Methods. p84 did not co-migrate near antigens defined by BP, CP, or 
EBA sera (data not shown). 
Expression of p84 in Epidermis As it is possible for dennis 
prepared from 1 M NaC.I-split ski.n to be contaminated by epider-
mal material, the follow1l1g expenment was co~ducted to exclude 
the possibility t1?at p84 was of eplderm~l ongm .. Nor~al human 
skin was split with 1 M NaCI, the dermiS and epidermiS were ex-
tracted similarly with 4% SDS + 2 M urea, and the extracts tested 
for presence of p84. The protein concentration of the epidermal 
extract was 1.56 mg and of dermal extract, 1.19 mg/ml. As illus-
trated in Fig 5, lane 1d, p84 was readily detected in the dermal 
extract but was absent in the epidermal extract. 
Similar results were obtained when the experiment was repeated 
using as a probe affinity-puri~ed ant!body to p84 (see. Fig 5, ~an~ 2d) . 
No staining of p84 was obta1l1ed US1l1g a control antibody similarly 
affinity purified from a strip cut from a portion of the nitrocellulose 
paper that did not conta.in p84. ~everal other bands were also s~en in 
the blots of affinity-punfied antl-p84, but these were non-speCific as 
they were also present in PBS and normal human serum control (see 
Fig 5, lanes 4d, 5d). These results indicate that no detectable p84 is 
present on the epidermal side of salt-split skin. 
Location of p84 Within the Basement Membrane To exam-
ine whether p84 is actually located in the basement membrane, 
Western blot affinity-purified antibody to this antigen was used to 
localize p84 in cryostat-cut sections of normal human skin by im-
munofluorescence. The affinity-purified antibody reacted only to 
p84 when tested by Western blot against dermal extracts (see Fig 5, 
1 
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2 3 4 5 
1. c. S. serum 
2 . Eluted 
anti-P84 lAb. 
3. Eluted 
control Ab. 
4. NHS 
5 . PBS 
ef• Epidermal extracts 
dJ.LDermal extracts, 
Figure 5. Western immunoblots of 4% SDS + 2 M urea extracts of epider-
mis (e) and dermis (d) of the same specimen of normal human skin reacted 
with CS staining serum (lalle 1), and with affinity-purified antibody to p84 
(la/Ie 2). Note that p84 is visua lized only in dermal extracts, indicating it is 
not an epidermal antigen contaminating the dermal extract. Latle 3, reaction 
with a control affinity-purified antibody; lalle 4, reaction with normal 
human serum; and 10 lie 5, reaction with PBS. Several bands in dermal extract 
with MW other than 84 kD are non-specific as they are also present in PBS 
control. 
lane 2d); and to the dermal-epidermal junction of cryostat-cut skin, 
indicating that it is a component of the basement membrane. Using 
1 M NaCI-split skin as a substrate, the antibody bound to the dermal 
side of the split (see Fig 6a), indicating p84 is located in the lower 
layer of the lamina lucida or below. Proteins eluted from the control 
strip did not react with human skin (Fig 6b). 
DISCUSSION 
Approximately 3 - 10% of individuals with basement membrane 
antibodies and subepidermal bullous diseases have an unusual re-
sponse characterized by CS antibodies that react to both the epider-
mal and dermal sides of salt-split skin [7,9,10,16]. This CS antibody 
response differs in both the appearance of the staining and in the 
pattern of the basement membrane antigens to which it is directed 
from the basement membrane antibodies typically associated with 
bullous pemphigoid or epidermolysis bullosa acquisita. The base-
ment membrane antibodies in bullous pemphigoid react to the epi-
a 
Figure 6. Immunofluorescence photomicrograph of 1 M NaCI-split nor-
mal human skin reacted with a) Western blot affinity-purified antibody to 
p84 and b) control affinity-purified antibody. Note that antibody to p84 
reacts only to the dermal side of the split. There is no reaction with control 
affinity-purified antibody. Scale bar, 100 J.l. 
240 GAO AND BYSTRYN 
dermal side of the split skin and in EBA to the dermal side [4]. 
whereas in CS sera they react to both sides [10,15]. The basement 
membrane antibodies in BP are directed predominantly to a major 
antigen of230 kD [6,11,14] and less often to a 160-180-kD minor 
antigen [6,17,18], which are both present only in epidermal extracts 
of skin, whereas in EBA they react to 145-kD and 290-kD antigens 
[7], present only in dermal extracts. 
Prior studies show that the antibodies in CS sera that are directed 
to the epidermal side of the split skin react to antigens of 230 and 
160/180 kDs, which resemble in their migration on SDS-PAGE 
and in their location in epidermal extracts the major and minor BP 
antigens [10]. However, unlike BP, the epidermal antibodies in CS 
sera are directed predominantly to the 160/180-kD antigen. These 
prior studies also indicated that CS sera contain additional antibod-
ies directed to unidentified dermal antigen(s) [10]. 
The results of the current study confirm that patients with CS 
sera have distinct antibodies to antigens present only on the dermal 
side of salt-split skin, and indicate that these antibodies are directed, 
at least in part, to an 82- 84-kD (p84) basement membrane antigen. 
The critical element in the identification of p84 was elucidating the 
appropriate conditions for extracting it from dermis. It was readily 
extracted with 4% SDS + 2 M urea; but not by homogenization 
and sonication in 2% SDS + 0.1 M DTT, which solubilizes bullous 
pemphigoid [11] and cicatrizing pemphigoid antigens or by 2% 
SDS + 8 M urea, which solubilizes the EBA antigen (7]. p84 is a 
normal component of human skin, as it was expressed in all speci-
mens studied. It is located in the basement membrane, as indicated 
by indirect immunofluorescence with affinity-purified antibody. 
Affinity-purified anti-p84 reacts only to the dermal side of 1 M 
NaCI-split skin, indicating this antigen is located in the deeper 
portion of the basement membrane, i.e., in the deep portion of the 
lamina lucida, in the lamina densa, or in the sublamina densa zone. 
p84 appears to differ from other basement membrane antigens 
involved in autoimmune bullous diseases. It is not related to the 
230-kD or to the 160/180-kD antigens associated with BP and CP 
because of differences in MW and because these antigens are located 
on the epidermal side of salt-split skin, whereas p84 is present on the 
dermal side. In addition, affinity-purified antibody to p84 does not 
react to either of these antigens, whereas, conversely, BP serum that 
normally contains antibodies to the 230- and 160/180-kD antigens 
does not react to p84. It is unlikely that p84 is a proteolytic break-
down product of the 160/180-kD, the 230-kD, or one of the small-
MW antigens that have on occasion been associated with BP 
[17,18], as these antigens should be localized on the epidermal side 
of split skin. p84 differs from the 145- and 290-kD EBA antigens 
based on differences in MW, in the fai lure of CS sera to react by 
immunoblot analysis to extracts of dermis that contain EBA anti-
gen, and in the failure of affinity-purified antibody to p84 to react to 
the EBA antigen. 
The findings of this study, together with our prior observations, 
indicate that CS sera contain multiple and distinct antibodies. Some 
of these are directed to antigens present on the epidermal side of 
salt-split skin, whereas others are directed to antigen(s) present only 
on the dermal side of the split. The possibility that the antibodies in 
combined staining sera are directed to a single antigen that straddles 
the zone split by 1 M NaCI is excluded by studies using affinity-
purified antibodies. These show that affinity-purified antibody to 
the 160-kD epidermal antigen reacts only to the epidermal side of 
split skin [10], whereas affinity-purified antibody to p84 reacts only 
to the dermal side. 
The clinical significance of antibodies to p84 remains to be deter-
mined. Patients with CS antibodies that react to p84 have a bullous 
eruption that clinically resembles bullous pemphigoid [12]. How-
ever, antibodies to p84 have not been found in patients with classical 
bullous pemphigoid (n = 9) or with other types of subepidermal 
blistering diseases associated with basement membrane antibodies 
that react only to the epidermal or to the dermal side of salt-split 
skin (cicatrizing pemphigoid [n = 6], acquired epidermolysis bul-
losa [n = 2]. bullous LE [n = 2]. Thus, one possibility is that pa-
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tients with this distinctive antibody response have a variant ofbul_ 
lous pemphigoid. They do not have classical BP, as their antibodies 
are directed to antigens that are present in a different anatomical 
location (on both the epidermal and dermal side of salt-split skin) 
and to a different pattern of antigens. Alternatively, and we believe 
more likely, the presence of an antibody response that is distinctive 
in terms of the pattern of antigens to which it is directed, the molec_ 
ular properties of some of these antigens, and the anatomical distri-
bution of the antigens within the basement membrane, suggest that 
patients with CS antibodies have a novel subepidermal autoimmune 
bullous disease, and that antibodies to p84 are a marker for this 
condition. 
In summary, patients with basement membrane antibodies that 
give a combined staining pattern on 1 M NaCI-split skin have a 
distinctive antibody response that differs from that seen in typical 
BP or EBA. The CS antibodies are directed in part to 160-kD and 
230-kD antigens located on the epidermal side of the split skin, and 
in part to an 84-kD basement membrane antigen located on the 
dermal side. 
This work was mpporled itl pari by USPHS Research Grants No. P30CA16087 
AR39749, and ROt AM 27663-09 and by fimds from Ille RJ/dolph Bae~ 
FOlmdaliotl. 
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